Exploring writing therapy for Asian American cancer survivors
Health Benefits of Writing Therapy Among Asian American Cancer Survivors
NA · M.D. Anderson Cancer Center · NCT06367959
This study tests whether writing therapy can improve the quality of life and reduce stress for Asian American breast cancer survivors.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 192 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | M.D. Anderson Cancer Center (other) |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Houston, Texas) |
| Trial ID | NCT06367959 on ClinicalTrials.gov |
What this trial studies
This study investigates the health benefits of writing therapy for Asian American breast cancer survivors. It aims to assess the impact of writing on quality of life and perceived stress at 6 and 12 months, as well as stress biomarkers at 3 months. The research employs mixed methods to explore the psychosocial and cultural factors that may contribute to the effectiveness of writing therapy. Participants will engage in writing essays and completing questionnaires to provide insights into their experiences.
Who should consider this trial
Good fit: Ideal candidates include Asian American adults aged 18 and older who have been diagnosed with stage 0-III cancer and have completed primary treatment within the last five years.
Not a fit: Patients who are unable to provide informed consent or do not identify as Asian or Asian American may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the mental well-being and quality of life for Asian American cancer survivors through therapeutic writing.
How similar studies have performed: Other studies have shown positive outcomes with writing therapy in various populations, suggesting potential success in this novel application for Asian American cancer survivors.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult (aged 18 and older) diagnosed with stage 0-III cancer (or acute leukemia in remission/ chronic myeloid leukemia in chronic phase). * Self-identified as Asian, Asian Americans, any Asian or Asian American subgroup (Chinese, Vietnamese, Indian, Korean, etc.) ethnic/cultural background * Completed primary treatment, including surgery, chemotherapy, and/or radiation therapy, immunotherapy, or targeted therapy within the preceding 5 years. * Comfortable reading in English or in Chinese. Exclusion Criteria: \- Inability to provide informed consent.
Where this trial is running
Houston, Texas
- MD Anderson Cancer Center — Houston, Texas, United States (RECRUITING)
Study contacts
- Principal investigator: Qian Lu, MD, PHD — M.D. Anderson Cancer Center
- Study coordinator: Qian Lu, MD, PHD
- Email: qlu@mdanderson.org
- Phone: (713) 745-8324
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Cancer